{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:11Z","timestamp":1787027291206,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","award":["406637\/2024-5"],"award-info":[{"award-number":["406637\/2024-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jval.2026.06.015","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:02:04Z","timestamp":1784044924000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence Mapping of Concepts, Methods, and Outcomes in the Evaluation of Diagnostic and Therapeutic Technologies for Ultrarare Diseases: A Systematic Scoping Review"],"prefix":"10.1016","author":[{"given":"Raul Edison","family":"Luna Lazo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Coelho","family":"Vilela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia Barbosa","family":"Domingues da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Helena","family":"Schroeder Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefany","family":"Scalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Tomoko","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inajara","family":"Rotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jval.2026.06.015_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"rare disease terminology and definitions\u2014A systematic global review: report of the ISPOR rare disease special interest group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2026.06.015_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104698","article-title":"Estimating the number of diseases \u2013 the concept of rare, ultra-rare, and hyper-rare","volume":"25","author":"Smith","year":"2022","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s13023-024-03392-7","article-title":"Epidemiological characterization of rare diseases in Brazil: a retrospective study of the Brazilian Rare Diseases Network","volume":"19","author":"de Oliveira","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.jval.2026.06.015_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Human Gen"},{"key":"10.1016\/j.jval.2026.06.015_bib5","author":"Roberts"},{"issue":"4","key":"10.1016\/j.jval.2026.06.015_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104346","article-title":"Drug development for neglected ultra-rare diseases of no commercial interest: Challenges and opportunities","volume":"30","author":"Katakowski","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jval.2026.06.015_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejpn.2023.12.003","article-title":"Ultra-rare ultra-care: assessing the impact of caring for children with ultra rare diseases","volume":"48","author":"Domaradzki","year":"2024","journal-title":"Eur J Paediat Neurol"},{"issue":"6","key":"10.1016\/j.jval.2026.06.015_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41587-021-00945-0","article-title":"A call to arms against ultra-rare diseases","volume":"39","author":"Crooke","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"140","key":"10.1016\/j.jval.2026.06.015_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1183\/16000617.0017-2016","article-title":"Why we should care about ultra-rare disease","volume":"25","author":"Harari","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib10","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1038\/s41467-025-61712-2","article-title":"Joint, multifaceted genomic analysis enables diagnosis of diverse, ultra-rare monogenic presentations","volume":"16","author":"Kobren","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jval.2026.06.015_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40258-025-01008-0","article-title":"Health technology assessment guidelines and recommendations across European union countries and the United Kingdom in rare disease and paediatric populations","volume":"24","author":"B\u00e1rtov\u00e1","year":"2026","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2026.06.015_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.zefq.2024.07.006","article-title":"Methodological approaches for generating robust evidence from trials in rare diseases","volume":"189","author":"Hilgers","year":"2024","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"156","key":"10.1016\/j.jval.2026.06.015_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0195-2020","article-title":"Ultra-rare disease: an European perspective","volume":"29","author":"Harari","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jval.2026.06.015_bib14","author":"Higgins"},{"issue":"10","key":"10.1016\/j.jval.2026.06.015_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"7","key":"10.1016\/j.jval.2026.06.015_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med. American College of Physicians"},{"key":"10.1016\/j.jval.2026.06.015_bib18","article-title":"Improving interactions between health technology assessment bodies and regulatory agencies: a systematic review and cross-sectional survey on processes, progress, outcomes, and challenges","volume":"7","author":"Ofori-Asenso","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jval.2026.06.015_bib22","author":"Pichon-Riviere"},{"key":"10.1016\/j.jval.2026.06.015_bib24","author":"Thomas"},{"key":"10.1016\/j.jval.2026.06.015_bib27","author":"Manipis"},{"key":"10.1016\/j.jval.2026.06.015_bib28","author":"Merlin"},{"key":"10.1016\/j.jval.2026.06.015_bib29","author":"Vogler"},{"key":"10.1016\/j.jval.2026.06.015_bib30","author":"Denis"},{"key":"10.1016\/j.jval.2026.06.015_bib50","author":"Vinhas"},{"key":"10.1016\/j.jval.2026.06.015_bib64","author":"Luis"},{"key":"10.1016\/j.jval.2026.06.015_bib65","author":"Vega-Coca"},{"key":"10.1016\/j.jval.2026.06.015_bib66","author":"Mart\u00edn"},{"issue":"6","key":"10.1016\/j.jval.2026.06.015_bib81","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jval.2026.03.2236","article-title":"The inequality-adjusted incremental cost-effectiveness ratio","volume":"29","author":"Cookson","year":"2026","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.06.015_bib82","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/ijerph21050616","article-title":"Fair funding decisions: consistency of the time horizons used in the calculation of quality-adjusted life years for therapies for very rare diseases by the national institute for health and care excellence in England","volume":"21","author":"Barman-Aks\u00f6zen","year":"2024","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jval.2026.06.015_bib83","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-026-01926-3","article-title":"Price development of orphan drugs in Germany after market access and subsequent assessments: a descriptive analysis","author":"Balg","year":"2026","journal-title":"The European Journal of Health Economics"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib84","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13023-022-02397-4","article-title":"HTA decision-making for drugs for rare diseases: comparison of processes across countries","volume":"17","author":"Stafinski","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.jval.2026.06.015_bib85","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40273-025-01538-4","article-title":"HTA evidence in rare diseases: just rare or also special?","volume":"43","author":"Basu","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2026.06.015_bib86","series-title":"Health technology assessment and appraisal of therapies for rare diseases. In: Rare Diseases Epidemiology: Update and Overview. Advances in Experimental Medicine and Biology","first-page":"221","author":"Iskrov","year":"2017"},{"issue":"5","key":"10.1016\/j.jval.2026.06.015_bib87","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jval.2018.03.002","article-title":"The problem of rarity: estimation of prevalence in rare disease","volume":"21","author":"Auvin","year":"2018","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2026.06.015_bib88","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41588-024-01836-1","article-title":"Next-generation phenotyping integrated in a national framework for patients with ultrarare disorders improves genetic diagnostics and yields new molecular findings","volume":"56","author":"Schmidt","year":"2024","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib89","first-page":"23","article-title":"A guide for the diagnosis of rare and undiagnosed disease: beyond the exome","volume":"14","author":"Marwaha","year":"2022","journal-title":"Genome Med. BioMed Central Ltd"},{"key":"10.1016\/j.jval.2026.06.015_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1510818","article-title":"A global survey about undiagnosed rare diseases: perspectives, challenges, and solutions","volume":"13","author":"Baldovino","year":"2025","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2019.07.017","article-title":"Differences in health technology assessment recommendations among european jurisdictions: the role of practice variations","volume":"23","author":"Vreman","year":"2020","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.06.015_bib92","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10198-024-01748-1","article-title":"How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals","volume":"26","author":"Gentilini","year":"2025","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib93","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-017-0690-5","article-title":"Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs","volume":"12","author":"Maeda","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jval.2026.06.015_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2023.104963","article-title":"Making recommendations to subsidize new health technologies in Australia: a qualitative study of decision-makers\u2019 perspectives on committee processes","volume":"139","author":"Sellars","year":"2024","journal-title":"Health Policy (New York)"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib95","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12913-025-12207-9","article-title":"The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada","volume":"25","author":"Hong","year":"2025","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib96","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462322003294","article-title":"Deliberative processes in decision making informed by health technology assessment in Latin America","volume":"38","author":"Alcaraz","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jval.2026.06.015_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2025.100138","article-title":"The global landscape of country-level health technology assessment processes: a survey among 104 countries","volume":"8","author":"Mirelman","year":"2025","journal-title":"Health Policy Open"},{"issue":"5","key":"10.1016\/j.jval.2026.06.015_bib98","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jval.2017.10.015","article-title":"Budgetary impact and cost drivers of drugs for rare and ultrarare diseases","volume":"21","author":"Schlander","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2026.06.015_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104346","article-title":"Drug development for neglected ultra-rare diseases of no commercial interest: challenges and opportunities","volume":"30","author":"Katakowski","year":"2025","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib100","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1186\/s12889-025-23831-9","article-title":"Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jval.2026.06.015_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2024.105080","article-title":"HTA criteria adopted in different models of public healthcare systems for orphan drugs: a scoping review","volume":"144","author":"Felippini","year":"2024","journal-title":"Health Policy (New York)"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13023-022-02397-4","article-title":"HTA decision-making for drugs for rare diseases: comparison of processes across countries","volume":"17","author":"Stafinski","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jval.2026.06.015_bib104","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13023-022-02217-9","article-title":"Rare disorders have many faces: in silico characterization of rare disorder spectrum","volume":"17","author":"Frederiksen","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jval.2026.06.015_bib105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/jebm.12266","article-title":"Gray literature: an important resource in systematic reviews","volume":"10","author":"Paez","year":"2017","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.jval.2026.06.015_bib106","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:48:36Z","timestamp":1787024916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S1098301526025350"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.015","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence Mapping of Concepts, Methods, and Outcomes in the Evaluation of Diagnostic and Therapeutic Technologies for Ultrarare Diseases: A Systematic Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}